Clinical trial
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
NCT00002505 · Hoag Memorial Hospital Presbyterian, Other · Completed
Key facts
| NCT number | NCT00002505 |
|---|---|
| Title | Tumor Cell Vaccine in Treating Patients With Advanced Cancer |
| Official title | RANDOMIZED PHASE II TRIAL OF AUTOLOGOUS TUMOR CELL VACCINE |
| Lead sponsor | Hoag Memorial Hospital Presbyterian, Other |
| Collaborators | Cancer Biotherapy Research Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | filgrastim, recombinant interferon gamma, tumor cell lysate vaccine therapy |
| Start date | Aug 1, 1992 |
| Primary completion | Aug 1, 2002 |
| Completion | May 1, 2006 |
| First posted | Jun 28, 2004 |
| Last update posted | May 12, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: